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Sequence variability associated with human immunodeficiency virus type 1 (HIV-1) is useful for inferring
structural and/or functional constraints at specific residues within the viral protease. Positions that are invariant
even in the presence of drug selection define critically important residues for protease function. While the impor-
tance of conserved active-site residues is easily understood, the role of other invariant residues is not. This work
focuses on invariant Thr80 at the apex of the P1 loop of HIV-1, HIV-2, and simian immunodeficiency virus protease.
In a previous study, we postulated, on the basis of a molecular dynamics simulation of the unliganded protease, that
Thr80 may play a role in the mobility of the flaps of protease. In the present study, both experimental and
computational methods were used to study the role of Thr80 in HIV protease. Three protease variants (T80V, T80N,
and T80S) were examined for changes in structure, dynamics, enzymatic activity, affinity for protease inhibitors, and
viral infectivity. While all three variants were structurally similar to the wild type, only T80S was functionally
similar. Both T80V and T80N had decreased the affinity for saquinavir. T80V significantly decreased the ability of
the enzyme to cleave a peptide substrate but maintained infectivity, while T80N abolished both activity and viral
infectivity. Additionally, T80N decreased the conformational flexibility of the flap region, as observed by simulations
of molecular dynamics. Taken together, these data indicate that HIV-1 protease functions best when residue 80 is
a small polar residue and that mutations to other amino acids significantly impair enzyme function, possibly by
affecting the flexibility of the flap domain.
Human immunodeficiency virus type 1 (HIV-1) protease is
an enzyme crucial to the life cycle of the virus (28). Inhibition
of the protease prevents viral maturation, and thus further
infection, making it a prime target in the treatment of HIV-1-
infected patients (8, 18, 53). Unfortunately, HIV-1 mutates
frequently because of the high replication rate of the virus (9)
and the infidelity of the reverse transcriptase (21, 50, 51). The
viral protease tolerates mutations in many areas of the se-
quence, especially mutations that decrease the binding affinity
of inhibitors without affecting the ability of the protease to
recognize and cleave its nine processing sites within the Gag
and Gag-Pro-Pol polyproteins. Such mutations cause drug re-
sistance. Many studies have explored residues susceptible to
mutation and their role in the development of drug resistance
(2, 14, 23, 24, 39, 41, 55). However, some amino acids in the
protease have not been observed to mutate, even in the pres-
ence of inhibitor therapy (58) (Fig. 1). While these conserved
residues potentially play a crucial role in either the structure or
the function of the enzyme, few studies have explored the
purpose of the invariant amino acids outside the active site.
Utilizing these residues could assist in the design of new classes
of protease inhibitors that may be less susceptible to develop-
ing resistance.
HIV protease, a homodimeric aspartyl protease, envelops its
substrate when the flap region of each monomer closes down
on the substrate sites within the Gag and Gag-Pro-Pol polypro-
teins. In a 10-ns molecular dynamics simulation (MD) of the
unliganded protease, the tips of the flaps (residues 47 to 53)
were observed to curl toward the protease core like fingers
curling toward the palm of a hand (57) (Fig. 1b). When the tip
of the flap curls inward, Ile50 contacts a number of predomi-
nantly hydrophobic residues in its own P1 loop (residues 78 to
83). The only polar residue in this region is virtually invariant
Thr80. Thr80 is one of only 27 (out of 99) residues that are
invariant in 99.9% of the sequences in the Stanford University
HIV Drug Resistance Database (58). The remaining 26 invari-
ant residues include the catalytic Asp-Thr-Gly triad, five other
glycines, three prolines, both tryptophans, and the tyrosine. Of
the 536 HIV-1, HIV-2, and simian immunodeficiency virus
protease sequences found in the Los Alamos National Labo-
ratory Database, residue 80 is 1 of only 10 residues invariant in
99.8% of the population. Additionally, numerous crystal struc-
tures show that the side chain hydroxyl group forms highly
conserved hydrogen bonds with the backbone of residue 82.
Other studies have observed structural changes in the P1 loop
when binding inhibitors and drug resistance mutations at
Val82 and Ile84 (1, 3, 17, 25–27, 37, 48). By examining invari-
ant residues within this loop, we may discover new ways to
target protease inhibitor therapy. Interactions between Thr80
and Ile50 could be important for destabilizing the burial of
Ile50 in a hydrophobic pocket and maintaining the mobility of
the flap tips. Thr80 could be important for stabilizing the P1
loop through its highly conserved hydrogen bond with Val82.
While the role of this residue has not been previously studied,
* Corresponding author. Mailing address: Department of Biochem-
istry and Molecular Pharmacology, University of Massachusetts Med-
ical School, 364 Plantation Street, Worcester, MA 01605. Phone: (508)
856-8008. Fax: (508) 856-6464. E-mail: Celia.Schiffer@umassmed.edu.
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the observation that Thr80 is invariant indicates that it is likely
important to protease structure and/or function.
In the present study, we used various methods to study the
role of Thr80. Native Thr80 was mutated to asparagine, serine,
and valine to generate protease variants referred to as T80N,
T80S, and T80V. The impact of Thr80 on HIV-1 protease
structure and function was investigated by a variety of biophys-
ical methods, including circular-dichroism (CD) spectroscopy,
tryptophan fluorescence, protein crystallography, MD simula-
tions, fluorescence resonance energy transfer, and isothermal
titration calorimetry. Additionally, the impact of these muta-
tions on the virus was examined by using a virus specific-
infectivity (SpIn) assay. Taken together, these data indicate
that Thr80 plays an important role in enzyme activity and help
to clarify why Thr80 does not mutate in vivo.
MATERIALS AND METHODS
Protease gene construction. The synthetic gene for the wild-type (WT) HIV-1
protease sequence was made with codons optimized for protein expression in
Escherichia coli and included a substitution of Gln7Lys to prevent autoproteoly-
sis (54). Residue 80 was mutated from threonine to three different amino acids,
asparagine, serine, and valine. Mutagenesis was performed with the Stratagene
QuikChange site-directed mutagenesis kit and confirmed by sequencing.
Protease expression and purification. The expression and purification of the
HIV-1 protease were previously described (26, 46). Briefly, the HIV protease
gene was cloned into plasmid pXC-35 (American Type Culture Collection,
Manassas, Va.) (7), which was transfected into E. coli TAP106. Transfected cells
were grown in a 12-liter fermentor and, following protein expression, lysed to
release the inclusion bodies containing the protease (20). Inclusion bodies were
isolated by centrifugation, and the pellet was dissolved in 50% acetic acid to
extract protease. High-molecular-weight proteins were separated from the de-
sired protease by size exclusion chromatography on a 2.1-liter Sephadex G-75
superfine (Sigma Chemical) column equilibrated with 50% acetic acid. Refolding
was accomplished by rapidly diluting the protease solution into a 100-fold excess
of refolding buffer. Excess acetic acid was removed through dialysis. Protein used
for crystallization was further purified with a Pharmacia Superdex 75 fast-per-
formance liquid chromatography column equilibrated with refolding buffer.
Far-UV CD spectroscopy. To determine the effects of mutations on the sec-
ondary structure of the protease, far-UV CD spectra were measured for the WT
and variant proteases with a JASCO J-810 spectrometer. The temperature was
maintained at 20°C with a Peltier temperature control device. Measurements
were made in a rectangular cell with a 1-mm path length. Each spectrum was
obtained by averaging three spectra recorded from 250 to 200 nm at a 0.5-nm
data pitch and a rate of 20 nm min1. The response time for each point was 8 s,
and the bandwidth was 2.5 nm. Protease concentrations were between 5 and 11
M in a buffer containing 10 mM sodium acetate at pH 5 and 2 mM Tris(2-
carboxyethyl)phosphine. Buffer scans were subtracted from the sample scans.
The mean residue ellipticity (MRE), in millidegrees per square centimeter per
decimole, was calculated with the equation MRE  /(10N  C  l), where  is
the measured signal in millidegrees, N is the number of residues, C is the molar
concentration of the protein, and l is the path length of the cuvette.
Tryptophan fluorescence. To further explore structural changes caused by
mutations at residue 80, tryptophan fluorescence was measured in the presence
and absence of saquinavir (SQV). Fluorescence was measured with a Photon
Technology International spectrofluorimeter at 25°C. The excitation wavelength
was 295 nm, and the emission spectrum was scanned from 300 to 500 nm in 1-nm
steps. Protease concentrations were between 5 and 5.5 M in a buffer containing
10 mM sodium acetate and 2 mM Tris(2-carboxyethyl)phosphine at pH 5. Buffer
scans were subtracted from the sample scans. Each variant was also examined for
changes in fluorescence upon inhibitor binding. Protease solutions were equili-
brated with 30 M SQV prior to measurement. Buffer scans containing SQV
were subtracted from the sample scans.
Protein crystallization. To look for more localized changes in the structures of
the proteases, T80N and T80S were crystallized with SQV, yielding the structures
SQVT80N and SQVT80S. Protein solutions between 1.16 and 1.75 mg ml1 were
equilibrated with a fivefold molar excess of the inhibitor SQV. Crystals were
grown by the vapor diffusion hanging-drop method. The reservoir solution con-
tained 126 mM sodium phosphate (pH 6.2), 63 mM sodium citrate, and 23 to
24% ammonium sulfate (25). The crystallization screens yielded rectangular
crystals, with the longest dimension being 0.1 mm.
Crystallographic data collection. The crystals were mounted within 0.2-mm
Hampton cryoloops and flash frozen over a nitrogen stream. Data were collected
on an in-house Rigaku X-ray generator with a Raxis IV image plate. Two
hundred fifty frames of 5-min exposures were collected per crystal with an
angular separation of 1° and no overlap between frames. Frames containing
unprocessed raw data were indexed with Denzo and scaled with ScalePack (35,
43). The SQVT80N and SQVT80S crystals diffracted to 1.5 Å and 2.0 Å, respec-
tively. Complete data collection statistics are listed in Table 1.
Structure solution and crystallographic refinement. The crystal structures
were solved and refined with the programs within the CCP4 interface (10). The
structures of SQVT80N and SQVT80S were solved with the molecular replacement
program AMoRe (40). The coordinates of the WT protease in complex with the
substrate (Protein Data Bank [PDB] code 1F7A) (47) were used as the starting
model. Upon obtaining the rotation and translation solutions, the molecular
replacement phases were further improved by using ARP/wARP (36) to build
solvent molecules into the unaccounted for regions of electron density. Subse-
quently, interactive model building was carried out with O (22). Initial 2Fo-Fc
and Fo-Fc maps unambiguously yielded the positions of SQV in each complex.
Conjugate gradient refinement with Refmac5 (38) was performed by incorpo-
rating the Schomaker and Trueblood tensor formulation of translation, libration,
and screw rotation parameters (30, 56, 61). The working R (Rwork) and its cross
validation (Rfree) were monitored throughout refinement. The geometry of the
structure was assessed with Procheck (31) at the end of each refinement round.
The refinement statistics are also shown in Table 1.
Isothermal titration calorimetry. To assess changes in the interaction between
each variant and SQV relative to that of the WT, the binding affinity and
enthalpy of interaction between each protease variant and SQV were measured
by competitive displacement isothermal titration calorimetry experiment (26, 42,
FIG. 1. HIV-1 protease colored by sequence conservation (58).
Residues colored red are invariant in both untreated and treated
populations of patients. Those colored yellow are invariant only in the
untreated population. Invariant glycine residues are colored blue. The
side chains of the catalytic aspartic acids (Asp25), Trp6, Trp42, and
Thr80 are displayed. (a) Unliganded protease structure (PDB code
1HHP). (b) Protease structure following 9-ns MD simulation.
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60, 62, 64) on a VP isothermal titration calorimeter (MicroCal Inc., Northampton,
MA). The buffer used for all protease and inhibitor solutions consisted of 10 mM
sodium acetate (pH 5.0), 2.0% dimethyl sulfoxide, and 2 mM Tris(2-carboxyethyl)
phosphine. A 25 to 30 M protease solution was saturated with 29 10-l injec-
tions of 0.3 mM pepstatin. The pepstatin was then displaced from the protease
by adding 29 10-l injections of 0.25 mM SQV. Heats of dilution were subtracted
from the corresponding heats of reaction to obtain the heat due solely to binding
of the ligand to the enzyme. The binding affinity and enthalpy of the interaction
between the protease and SQV were obtained by using the Origin7 software to
subtract the enthalpy and binding affinity of pepstatin from the final displace-
ment reaction. Direct SQV titration experiments were performed for T80N
because this variant did not bind pepstatin and the direct titration of SQV versus
this variant yielded high-quality results. Twenty-nine 10-l aliquots of 0.2 mM
SQV were injected into solutions containing 22 to 40 M protease. Data were
processed and analyzed with the MicroCal Origin7 software package. Final
results represent the average of three measurements.
Enzymatic activity. Changes in the catalytic activity of each protease variant
were assessed by measuring each variant’s ability to hydrolyze the fluorogenic
substrate Arg-Glu(EDANS)-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln-Lys(DABCYL)-
Arg (Molecular Probes, Eugene, OR) (34). Fluorescence reactions were moni-
tored by exciting solutions at 340 nm and recording emitted light at 490 nm in a
Photon Technology International spectrofluorimeter. Substrate solution (190 l)
was placed in a 3-mm rectangular cuvette, and baseline fluorescence was mea-
sured. The reaction was initiated by adding 10 l of 2 M HIV-1 protease
solution. After 20 s (the time needed for manual mixing), data points were
acquired every 2 s. At substrate concentrations above 10 M, results were tainted
by the inner-filter effect (11). The fluorogenic substrate was dissolved in 1 M
sodium chloride–0.1 M sodium acetate–1 mM EDTA–1 mM dithiothreitol–4%
dimethyl sulfoxide–1 mg/ml bovine serum albumin at pH 4.7, and the experi-
ments were done at 25°C. The baseline fluorescence of the substrate solution was
subtracted from the reaction fluorescence. The increase in fluorescence was
monitored in real time, and when there was no further increase in fluorescence
the reaction was considered complete. Initial data analysis showed that the Km
was above 10 M and Km and kcat could not be separately determined. There-
fore, kcat/Km was determined with substrate concentrations below Km (11). The
increase in fluorescence over time was fitted by Kaleidagraph (v 3.6) to the
equation y  m1  m2  1  em3  x, where m1 is the initial fluorescence,
m2 is the total increase in fluorescence, and m3 is [E]  kcat/Km. For each
protease variant that reacted with the fluorescent substrate, kcat/Km was calcu-
lated at concentrations of 2, 5, and 10 M substrate. The average kcat/Km was
calculated over nine values, three at each substrate concentration.
SpIn assay. The SpIn assay was performed as described by G. J. Henderson et
al. (unpublished data). Mutations were introduced into the protease region of a
plasmid subclone of the NL4-3 strain of HIV-1 by the QuikChange strategy. The
mutagenized subclone was verified completely by sequence and then introduced
into a full-length clone of NL4-3 called pNL-CH. Two clones of each mutant
were isolated, and the protease nucleotide sequence was confirmed. The mu-
tagenized plasmids were used to generate infectious virus by transfecting 293
cells that were plated at a density 3  105 per well of a 24-well plate 1 day prior
to transfection. Triplicate transfections of 0.5 g of each plasmid DNA were
done with each mutant plasmid with Fugene transfection reagent (Roche) ac-
cording to the manufacturer’s instructions. The parental WT plasmid was trans-
fected in parallel, also in triplicate, for direct comparison with the mutants. After
48 h, virus-containing culture supernatants were collected, clarified of cellular
debris by centrifugation at 3,000  g and 4°C for 5 min, and then stored at
80°C. The amount of capsid protein (p24) in the culture supernatants was
measured by an enzyme-linked immunosorbent assay with reagents available
from the National Cancer Institute AIDS Vaccine Program. The manufacturer’s
instructions were followed, except that samples were mixed with sodium dodecyl
sulfate (final concentration, 1% [wt/vol]) and incubated at 100°C for 5 min for
virion lysis. All samples were measured in duplicate at two dilutions, and the
masses were calculated from the standard curve by using the average optical
density of the duplicate measurements. Virus particles were also analyzed by
Western analysis as described previously (49), with a polyclonal anti-p24 anti-
body (NIH AIDS Research and Reference Reagent Program, 4250). Briefly,
virus particles in the medium supernatant of transfected cultures were collected
by centrifugation and lysed. The lysed viral proteins were resolved by polyacryl-
amide gel electrophoresis under denaturing and reducing conditions, and the
proteins were then transferred to a membrane and probed with an anti-p24
antibody.
The infectivity of the mutant viruses was measured by infecting TZM-bl cells
(AIDS Research and Reference Reagent Program, National Institutes of
Health) that were seeded at 1.3  104 cells per well of a 96-well plate 24 h prior
to infection. After a 48-h incubation with the virus, the cells were washed with
150 l of Dulbecco’s phosphate-buffered saline, lysed with 50 l of luciferase
reporter lysis buffer (Promega), and stored at 80°C. The samples were subse-
quently thawed. The amount of luciferase activity present was quantified over a
4-s interval when 50 l of luciferase reagent (Promega) was injected in each well
with a FLUOstar fluorescence plate reader (BMG LABTECH) to record the
number of relative light units emitted. SpIn, calculated as the number of relative
light units per nanogram of infecting capsid protein, was normalized to the
parental strain, which was given a SpIn value of 1.
MD. To study the impact of mutating residue 80 on the conformational
flexibility of HIV-1 protease, separate MD simulations were run for the WT and
three protease variants, T80S, T80N, and T80V. The initial coordinates were
taken from the 9-ns time point of a previous simulation where the protease flap
tips were already folded in toward the P1 loop (57). Each mutation (serine,
asparagine, or valine) was modeled by MIDAS (16) into residue 80 in both
monomers, and MD simulations were started with the AMBER8 software pack-
age (6). Histidine residues were protonated at the epsilon nitrogen. Two hundred
cycles of restrained steepest-descent energy minimization were performed on
each structure. The protein was restrained with a harmonic force constant of 9.55
kcal mol1 Å2. Each structure was solvated with a TIP3P water box to allow for
at least 8 Å of water on each face of protease. The initial periodic box dimensions
were 82.2 by 82.6 by 80.4 Å3. Approximately 14,000 water molecules were added
to each system, and 1,000 cycles of steepest-descent energy minimization were
performed, keeping the protein fixed. Equilibration of the system continued with
5,000 steps of restrained MD with a 9.55-kcal mol1 Å2 force constant and
constant temperature (300 K) and pressure (1 atm). This equilibration was
followed by 25,000 steps of unrestrained MD. The data-collecting portion of the
simulation was performed at constant temperature and pressure for 5 ns with 1-fs
time steps.
RESULTS
The role of residue 80 in the structure, function, and viral
infectivity of the HIV-1 protease was investigated in three
variants, T80N, T80V, and T80S.
TABLE 1. Crystallographic statistics of variant HIV-1 proteases
T80S and T80N in complex with SQVa
Parameter SQVT80S SQVT80N
Data collection
Space group P212121 P212121
Z 4 4
a (Å) 50.50 50.52
b (Å) 57.93 58.18
c (Å) 61.62 61.52
Resolution (Å) 2.0 1.5
Total no. of reflections 88,158 123,033
No. of unique reflections 12,625 29,647
Rmerge (%) 7.3 4.2
Completeness (%) 99.1 99.3
I/	I 8.2 17.7
Refinement
Rwork value (%) 17.6 17.1
Rfree (%) 23.2 19.8
Rwork  Rfree (%) 17.9 17.3
RMSD
Bond length (Å) 0.008 0.005
Bond angle (°) 1.6 1.4
No. of waters 130 193
No. of phosphates 5 6
PDB code 1FGU 1FGV
a RMSD, root mean square deviation.
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General structural changes. Effects of the three mutations
on the secondary structure of the HIV-1 protease were probed
by far-UV CD spectroscopy. Since HIV-1 protease is a pre-
dominantly 
-sheet protein, any mutation that dramatically
disrupted the structure would decrease the 
-sheet content of
the protein and increase its MRE at 216 nm. As shown in Fig.
2a, the three variants had secondary structures similar to that
of the WT, comparable to previously published results (65).
The spectrum of T80V was almost identical to that of the WT
protease, and within the accuracy of protein concentration
measurements, those of T80S and T80N were similar to that of
the WT. The overall resemblance among these spectra indi-
cates that these proteases were all folded similarly.
To further examine any structural changes caused by muta-
tions at residue 80, tryptophan fluorescence was measured for
all variants. Each protease monomer has two tryptophans,
Trp6 at the dimer interface and Trp42 at the end of the flap
region (Fig. 1). The fluorescence of the native tryptophans was
measured for the WT protease and each variant in the pres-
ence and absence of SQV. The emission spectra for T80V,
T80S, and T80N were similar to that of the WT, indicating that
the tryptophans in the Thr80 protease variants are in an envi-
ronment similar to that of those in the WT protease (Fig. 2b).
For both the WT and variant proteases, the presence of SQV
led to a 10% decrease in the observed tryptophan fluorescence,
suggesting that SQV interacts with all of these proteases. How-
ever, these results did not provide information on how this
interaction may have been altered by mutation at Thr80.
Thermodynamic parameters of inhibitor binding. To reveal
any altered interactions between SQV and the Thr80 variant
proteases, the binding affinity and thermodynamic parameters
of each variant and WT with respect to SQV were determined
by isothermal titration calorimetry (Table 2). SQV was chosen
because it is a well-characterized protease inhibitor (12, 15, 19,
29, 33, 52, 64). SQV is an entropically driven inhibitor. As SQV
is a fairly hydrophobic molecule, it likely causes surrounding
water molecules to become ordered. The favorable entropy
observed in the reaction between the HIV-1 protease and SQV
is presumably due to the release of this ordered water when
SQV is sequestered within the active site of the protease. The
free energy of binding of T80N and SQV was 4.2 kcal mol1
worse than that between the WT and SQV. This decreased
binding affinity was associated with larger changes in the en-
thalpy and entropy of the reaction. The entropy of T80N bind-
ing to SQV was 13.4 kcal mol1 more favorable than that of
the WT, while the enthalpic contribution was 17.7 kcal mol1
less favorable. Similarly, a small decrease in binding affinity
between T80V and SQV was associated with larger changes in
the enthalpy and entropy of the reaction. While the free energy
of the reaction between T80V and SQV decreased by 0.5 kcal
mol1 relative to that of the WT, the entropy of SQV binding
was 4.5 kcal mol1 more favorable and the enthalpy of the
reaction was 5.0 kcal mol1 less favorable than its binding to
the WT. In contrast to the other two variants, there was no
change within error in the free energy of the reaction between
T80S and SQV relative to that of the WT. While the entropy
of T80S binding to SQV was 0.5 kcal mol1 more favorable
than that of WT binding to SQV, the free energy of the reac-
FIG. 2. General structural features of WT and variant proteases
(WT, black; T80V, red; T80N, yellow; T80S, green). (a) Far-UV CD
spectra of WT and variant proteases. (b) Tryptophan fluorescence
spectra of WT and variant proteases, unbound and bound to SQV. The
unliganded WT protease is shown as a solid line, and the unliganded
variant proteases are shown as filled symbols. The WT protease bound
to SQV is shown as a dotted line, and the variant proteases are shown
as empty symbols. AU, arbitrary units.
TABLE 2. Binding thermodynamics of SQV at 20°C
Protease Ka (M1) Kd (nM) Kd ratio
H
(kcal mol1) H
TS
(kcal mol1) (TS)
G
(kcal mol1) G
WT (2.0  0.1)  109 0.50  0.03 3.6  0.1 16.1 12.5
T80S (1.5  0.1)  109 0.66  0.05 1.3 4.2  0.3 0.6 16.5 0.4 12.3 0.2
T80V (8.8  0.1)  108 1.1  0.02 2.3 8.6  0.3 5.0 20.6 4.5 12.0 0.5
T80N (1.3  0.1)  106 760  43 1.5  103 21  1.7 18 29.5 13 8.2 4.3
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tion was maintained at approximately the same value by 0.7
kcal mol1 less favorable enthalpy. The thermodynamic pa-
rameters of all reactions were measured with SQV. Therefore,
the changes in enthalpy and entropy were likely due exclusively
to changes in the free and bound states of the enzyme between
the variants. Both the Thr80Val and Thr80Asn mutations de-
creased the binding affinity of protease for SQV, and all three
mutations affected the thermodynamics of binding between the
protease and SQV, demonstrating the importance of Thr80 in
the activity of the protease.
Enzymatic activity. An assay of enzymatic activity was used
to further verify the importance of Thr80 to protease function.
Each variant protease was examined for deleterious effects on
activity relative to the WT through comparison of the ability of
each variant to cleave a fluorogenic MA-CA substrate. Both
the WT and T80S completely cleaved all of the fluorescent
substrate within 10 min (Fig. 3a). T80V required more than 2 h
to completely cleave all of the substrate. T80N was not able to
cleave the substrate. The catalytic efficiencies, kcat/Km values,
of the WT and T80S were 7.4  102 M1s1 and 8.4  102
M1 s1, respectively (Table 3), indicating greater catalytic
activity for the T80S variant. The kcat/Km of T80V was 4.5 
103 M1s1, a 16-fold decrease relative to that of the WT.
The impact of the Thr80Val and Thr80Asn mutations on pro-
tease activity further confirms the importance of Thr80 in
protease function.
Viral infectivity. A SpIn assay of viral fitness was performed
with the Thr80 mutants to provide information about the pro-
teases’ abilities to cleave the substrate sites necessary for viral
maturation. The measured infectiousness of both the T80S
virus and the T80V virus was within twofold of that of the WT
virus. The apparent discrepancy between the enzymatic activity
and the SpIn was probably due to the fact that the MA-CA
cleavage site is not the rate-determining step in viral matura-
tion (32, 44, 45, 63). This indicates that, despite impaired
activity versus the MA-CA site, T80V was still able to cleave
other sites with sufficient efficiency to maintain nearly WT
levels of infectivity. In contrast, the T80N virus had very low
levels of infectivity. When we examined the extent of process-
ing by Western analysis (Fig. 3b), we found that the T80N virus
were composed of mostly unprocessed Gag, similar to a D25A
protease active-site mutant virus. In contrast, the T80S virus
and the T80V virus were composed of Gag that had been
largely processed although to a lesser extent than the WT virus.
Structures of protease-SQV complexes. The Thr80Asn
mutation consistently impaired protease activity, while the
Thr80Ser mutation did not affect protease activity. To deter-
mine what structural changes were causing the observed effect
on protease activity, T80N and T80S were crystallized with
SQV, yielding the structures SQVT80S and SQVT80N, with
2.0-Å and 1.5-Å resolutions, respectively. These structures
were submitted to the PDB and assigned codes 1FGU and
1FGV, respectively. The electron density of both SQV and the
mutated side chains was unambiguous, and there were no
crystal contacts between the mutated side chains and surround-
ing protease molecules. The crystallographic statistics for these
structures are listed in Table 1. The PDB structure of the WT
HIV-1 protease bound to SQV (PDB code 1HXB) (29) has
SQV in two orientations. In order to obtain the most accurate
comparison between structures and because T80S behaved just
as the WT did, the SQVT80N and SQVT80S structures were
compared with each other. To look for changes between the
SQVT80N and SQVT80S structures, difference distance plots
with the C backbone of each structure were generated com-
paring the two protein variants (Fig. 4). This plot shows that
one monomer of the SQVT80N structure underwent significant
FIG. 3. Mutation at residue 80 affects protease activity. (a) Enzy-
matic activity. The increase in fluorescence over time observed when
10 l of a 2 M protease solution was mixed with 190 l of 2 M
fluorescent substrate is shown. Both the WT (black) and T80S (green)
completely cleaved the fluorescent substrate within 10 min. The initial
burst in fluorescence occurs during the 20 s required for mixing. T80V
(red) required 10 min to reach the same fluorescence that the WT and
the T80S variant achieved in the first 20 s. The T80N (yellow) variant
had virtually undetectable increases in fluorescence. AU, arbitrary
units. (b) Western analysis of mutant virus particles. Lane 1, pNLCH
used as the WT; lane 2, T80S mutant; lane 3, another clone of the T80S
mutant; lane 4, T80V mutant; lane 5, T80N mutant; lane 6, another
clone of the T80N mutant; lane 7, D25A active-site mutant of the
protease used as a control for a negative processing phenotype. Mo-
lecular size markers were included in the gel, and their migration
positions (sizes are in kilodaltons) are shown on the right.
TABLE 3. Catalytic efficiencies of WT and variant proteases
Protease kcat/Km (M1 s1)
WT......................................................................... (7.4  0.5)  102
T80S ...................................................................... (8.4  1.3)  102
T80V...................................................................... (4.5  2.0)  103
T80N......................................................................No detectable activity
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structural rearrangement to accommodate asparagine, while
the other monomer was able to accommodate the larger side
chain without altering the position of the main chain atoms of
the protease.
While residue 80 is not in the active site of the protease, it is
bound to and contacts residues directly involved in ligand bind-
ing. Therefore, a mutation at this residue could cause signifi-
cant rearrangement of the protease with inhibitor bound. As
shown in the double difference distance plot, the distance be-
tween residues Pro79 through Val82 and most regions of the
protein increased by more than 0.5 Å in SQVT80N relative to
SQVT80S. The most significant increases were with residues in
both flap regions, Lys43-Gln58 and Lys43-Gln58 and the P1
loop in the opposite monomer, Pro79-Val82. In SQVT80N,
the side chain of Asn80 folded back on itself (Fig. 5a). Relative
to Ser80, this conformation of Asn80 increased its interaction
with Val32 and Leu33 and formed a hydrogen bond between
Asn80 OD and Pro79 N. The side chain amide nitrogen of
Asn80 and the side chain carboxyl oxygen of Ser80 maintained
the conserved hydrogen bond with the backbone oxygen of
Val82. However, the conformation of Asn80 altered the P1
loop relative to its position in SQVT80S, pulling Pro81 back
from the 2-methyl-decahydroisoquinoline-3-carboxylic acid-
P1 (DiqP1) group of SQV and Val82 toward DiqP1. In
SQVT80N, SQV lost a contact with Pro81, which was above it,
when the distance between Pro81 CG and DiqP1 C5 increased
by 0.7 Å and gained a contact with Val82, which was below it,
when the distance between Val82 CG1 and DiqP1 C6 de-
creased by 0.9 Å in SQVT80N relative to SQVT80S. Figure 6b
shows contacts that decreased by more than 0.2 Å in
SQVT80N relative to SQVT80S, and the opposite information
is displayed in Fig. 6a. These results emphasize that struc-
tural rearrangement of the P1 loop can significantly alter the
interactions between the protease and SQV.
Although one monomer of the SQVT80N structure had re-
arranged the P1 loop relative to SQVT80S, the other monomer
did not undergo any repositioning of its main chain atoms
relative to the SQVT80S structure. As shown in the double
difference plot, the distance between 80 C and other residues
was not significantly different between the SQVT80N and
SQVT80S structures, indicating that when the protease variants
were bound to SQV, the protease was able to accommodate
asparagine at residue 80. Asn80 adopted a conformation sim-
ilar to that of Ser80 (Fig. 5b), and both residues formed the
same hydrogen bonds with the main chain atoms of Pro81 and
Val82. A significant difference between the two structures was
the presence of a water molecule in the SQVT80N structure
between Ile50 and residues Pro79 and Pro81 that was not
observed in the SQVT80S structure. This water molecule forms
FIG. 4. Difference distance plots of SQVT80N versus SQVT80S. Rel-
ative changes in the distance between two alpha-carbon atoms in the
SQVT80S structure versus the SQVT80N structure are shown. Green,
blue, and red contours distinguish the ranges 1.0 to 0.5 Å, 0.5 to 1.0
Å, and 1 Å and above, respectively.
FIG. 5. P1 loops of the crystal structures of SQVT80N and SQVT80S
superimposed. Side chain oxygen atoms are in red, and side chain
nitrogen atoms are in blue. Water molecules within 5 Å of residue
80 are shown as van der Waals spheres. (a) Asn80 (SQVT80N, yellow;
SQV, orange) and Ser80 (SQVT80S, green; SQV, cyan) adopt very
different conformations in the P1 loop. (b) Asn80 and Ser80 adopt
similar conformations, and the P1 loops in this monomer are not
significantly different between the two structures. The modeling pro-
gram MIDAS (16) was used to superimpose the two protease struc-
tures, SQVT80N and SQVT80S, on the basis of the highly conserved
terminal region (positions 1 to 9 and 86 to 99).
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one hydrogen bond with the side chain amine group of Asn80,
one contact with SQV, and numerous contacts with both main
chain and side chain atoms of Ile50, Pro79, Asn80, and
Pro81. Despite the increased size of asparagine and the pres-
ence of the extra water molecule, there was remarkable simi-
larity of this monomer between the structures. However, there
was some structural rearrangement of SQV and a few varia-
tions in the van der Waals contacts made between the protease
and SQV. There was one contact between Asn80 and the
phenylalaninol-P1 group of SQV not observed in the SQVT80S
structure. Conversely, the distance between Pro81 and the
phenylalaninol-P1 and 2-carbonylquinoline-P3 groups was in-
creased by more than 0.2 Å in SQVT80N relative to SQVT80S.
Two van der Waals contacts were lost between SQV and the
SQVT80N variant protease because of this increased distance
(Fig. 6). This indicates that, in contrast to the structural rear-
rangements observed by residues Pro79 and Val82, the altered
interactions between SQV and protease in this monomer are
due to rearrangements of SQV to accommodate Asn80.
Interactions between SQV and the protease flap region dif-
fered between SQVT80N and SQVT80S. These changes were
caused by the structural modifications that were made by either
the P1 loops or SQV. For example, in the SQVT80S structure,
the DiqP1 group has the most van der Waals contacts with the
flap region while in the SQVT80N structure, the asparagine-P2
group of SQV had the most contact with the flap region. The
2-carbonylquinoline-P3 group of SQV was closer to Gly48, and
asparagine-P2 moved closer to Ile50 in SQVT80N relative to
their distance in SQVT80S. Thus, substitution of asparagine at
residue 80 was able to indirectly affect the flap region in the
bound protease.
Changes in flap dynamics. In order to further examine the
role of residue 80 in the structure and conformational flexibil-
ity of the flap region of the unbound protease, a separate MD
simulation was performed for the WT and each variant pro-
tease, T80V, T80N, and T80S. Each simulation was started
from the 9-ns structure of the previous MD simulation (57)
since the flap region was already folded in toward the P1 loop
FIG. 6. Differences in van der Waals contacts between the protease and SQV in the SQVT80S and SQVT80N crystal structures. Distances
between these two structures that changed by more than 0.2 Å were considered significant. Side chain oxygen atoms are in red, and side chain
nitrogen atoms are in blue. (a) van der Waals spheres are used to show contacts between protease atoms and SQV atoms that decreased by more
than 0.2 Å in SQVT80S relative to SQVT80N. (b) van der Waals spheres are used to show contacts between protease atoms and SQV atoms that
decreased by more than 0.2 Å in SQVT80N relative to SQVT80S.
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in this structure. Because these were relatively short simula-
tions and nothing was restraining the protease, the two mono-
mers in each simulation exhibit two conformational samplings
of protease monomers. Figure 7 shows four time snapshots
from the four simulations at 0 ns, 1.5 ns, 3 ns, and 4.5 ns. The
WT, T80S, and T80V simulations sampled similar conforma-
tional spaces. Although each monomer moves separately, in all
three simulations the protease flap region unfolds into the
solvent. To quantify the range of motion of the protease flaps
in each simulation, the distance between residue 50 and resi-
due 80 in both monomers in all of the simulations was moni-
tored over time. In the WT, T80V, and T80S simulations, the
distance between these two residues fluctuated between 5 and
22 Å in both monomers. In one monomer of the T80S simu-
lation, the space sampled by the flap region was significantly
decreased, relative to the WT and its other monomer, because
of a hydrogen bond between the backbone oxygen of Pro79
and the backbone nitrogen of Ile50. After approximately 3.5
ns, that hydrogen bond was broken and the flap began to
unfold into the solvent. In contrast to the other simulations,
the flaps within the T80N simulation did not unfold into the
solvent. As shown in Fig. 7, there was decreased flexibility in
both flap regions in the T80N simulation relative to the other
protease variants. The distance between Asn80 and Ile50 fluc-
tuated between 7 and 17 Å in one monomer and between 6 and
8 Å in the other monomer. In this simulation, the flap region
with decreased movement was bound to the P1 loop by two
hydrogen bonds, one between the side chain oxygen of Asn80
and the backbone nitrogen of Gly49 and the other between the
backbone oxygen of Pro79 and the same backbone nitrogen of
Gly49. In the other monomer, there was not a specific hydro-
gen bond between the flap region and the P1 loop, yet this flap
remained curled toward the P1 loop for most of the simulation.
This was probably due to water bridging hydrogen bonds be-
tween the flap and Asn80. These results demonstrate that
substituting a large polar residue for threonine at residue 80
can significantly and detrimentally affect the conformational
flexibility of the flap region. However, substitution of a non-
polar residue did not impact the ability of the protease flap to
unfold into the solvent.
As mentioned previously, there is a conserved hydrogen
bond between the side chain of residue 80 and the backbone of
residue 82. In these simulations, the existence of this hydrogen
bond over time was monitored, except in the T80V simulation,
where no hydrogen bond can exist. In the WT simulation, this
hydrogen bond existed less than 10% of time, and in the T80S
simulation it existed less than 1% of the time. It did not exist
in the T80N simulation. As shown in Fig. 7, this hydrogen bond
was not required to maintain the stability of the P1 loop. These
simulations provide interesting insights into the impact of vari-
ation at residue 80 on protease dynamics and may help to
explain the results seen in the various activity assays described
above.
DISCUSSION
Many residues within the HIV-1 protease are susceptible to
mutation, especially under the selective pressure of therapy;
FIG. 7. Snapshots from the four MD simulations at 0.0, 1.5, 3.0, and 4.5 ns (WT, black; T80V, red; T80S, green; T80N, yellow). The flap region
in the WT, T80V, and T80S simulations unfolded into the solvent within 4.5 ns. In the T80N simulations, the flap region was less mobile.
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therefore, those residues that are invariant despite therapy are
likely important to enzyme structure and/or function. Thr80,
which is invariant in the HIV-1, HIV-2, and simian immuno-
deficiency virus proteases, regardless of protease inhibitor
treatment, is one such residue. While not directly involved in
ligand binding, it is located on the edge of the active-site cavity
in the middle of the P1 loop. To examine the role of this
residue in protease, we constructed three protease variants,
T80S, T80N, and T80V, and used a variety of biochemical
techniques to characterize its role in the structure, dynamics,
and function of protease. Additionally, a viral infectivity assay
was used to examine the impact of changes at residue 80 on the
virus as a whole. The results indicate that mutation at this site
can detrimentally impact the enzymatic activity, decrease viral
infectivity, alter the enthalpy and entropy contributions to in-
hibitor binding, and likely decrease the conformational flexi-
bility of the HIV-1 protease.
Of the three variants studied, T80S had the least impact on
protease structure and function. This variant had a slightly
increased kcat/Km relative to the WT but no substantial change
in its affinity for SQV and only an approximately twofold effect
on viral infectivity. Thus, this mutation does not appear to give
the virus any selective advantage or cause any resistance to
SQV. Further studies are needed to clarify why Thr80Ser does
not occur as a natural variant. Regardless of the amino acid at
residue 80, all of the protease variants had structures similar to
that of the WT (Fig. 2). Two variants, T80S and T80N, were
crystallized with the inhibitor SQV. The structures were re-
markably similar, except that the Thr80Asn mutation led to a
structural rearrangement of the P1 loop in one monomer rel-
ative to the SQVT80S structure (Fig. 5) that altered the van der
Waals contacts of T80N relative to those of T80S (Fig. 6).
Despite the rearrangement of this loop, the asparagine at this
site was able to form hydrogen bonds with Val82. In fact,
maintenance of this hydrogen bond maybe what led to the
rearrangement of the P1 loop in this monomer. The hydrogen
bond between the side chain of residue 80 and the backbone of
Val82 was also observed in the other monomer of SQVT80N
and in both monomers of SQVT80S. Thus, an important role of
Thr80 in the bound protease appears to be the formation of
this hydrogen bond.
While this hydrogen bond was conserved in the crystal struc-
tures, it was not conserved in the MD simulations of unbound
protease. MD simulations were performed on all variant pro-
teases and on the WT. In the WT, T80S, and T80N simula-
tions, residue 80 was capable of forming a hydrogen bond
between its side chain and the backbone of Val82. However,
this hydrogen bond existed only intermittently in the WT and
T80S simulations and did not exist in the T80N simulation.
Without the hydrogen bond between residue 80 and Val82, the
P1 loop itself was still structurally stable. Actually, residue 80
appeared to have the most significant impact on the flexibility
of the flap region. In the WT, T80S, and T80V simulations, the
flap region uncurled into the solvent (Fig. 7). This was some-
what surprising in the T80V simulation because our original
hypothesis was that polar Thr80 prevented Ile50 from packing
into the hydrophobic pocket formed by other residues sur-
rounding the P1 loop. Unexpectedly, the polar asparagine at
residue 80 prevented the flap from uncurling by forming elec-
trostatic interactions with the flap region, limiting its flexibility.
While crystal structures of the bound protease would not sug-
gest that residue 80 is involved in flap dynamics, MD simula-
tions illustrate a potential role for this site in flap dynamics.
Although residue 80 is not in the active site of the protease,
it is bound to and contacts numerous residues involved in
ligand binding. Therefore, mutations at this site could have an
indirect role in the function of the protease. The examination
of T80V and T80N indicates that Thr80 may not mutate to less
chemically similar amino acids because of significant effects of
protease activity. The catalytic efficiencies of T80S, T80V, and
the WT were determined with a fluorescently labeled peptide
substrate whose sequence is based on the MA-CA site of the
HIV-1 protease (34). The catalytic efficiency of T80N versus
this substrate could not be measured. While T80S had essen-
tially WT activity, T80V only retained 6% of the WT protease’s
ability to cleave the MA-CA site. In order to examine the
impact of these mutations at residue 80 on the virus as a whole,
the SpIn of each variant was determined. As expected, the
T80N virus was not infectious. However, the T80S virus and
the T80V virus were within twofold of the infectiousness of the
WT virus and had only slightly decreased processing of Gag
relative to the WT virus. The discrepancy between the SpIn
and catalytic efficiency results is likely due to the fact that the
MA-CA cleavage is not the rate-determining step in viral mat-
uration. Previous work with 14 fluorescently labeled peptide
substrates of the HIV-1 protease determined that the catalytic
efficiency of the WT protease cleaving the MA-CA site was
320-fold more efficient than the cleavage of the NC-p1 site
(32). Mutations within the protease differentially impact the
processing of the various substrates, and perhaps the Thr80Val
mutation in the protease does not affect the rate-determining
cleavage steps in viral maturation as dramatically as it affects
the cleavage of the MA-CA site.
The role of residue 80 in the HIV-1 protease was further
elucidated by examining a combination of crystal structures,
MD simulations, and isothermal titration calorimetry. Through
isothermal titration calorimetry, we found that the inhibitor
SQV binds 2.3-fold more weakly to T80V than to the WT and
1,500-fold more weakly to T80N. In each case, the decrease in
binding affinity is due to a much less favorable enthalpy of the
interaction, which decreased by 5 and 17.7 kcal mol1, respec-
tively, for T80V and T80N. This decrease possibly indicates a
structural change in the bound state of protease between the
variants, as seen in the crystal structure of T80N, where there
was an obvious rearrangement of the residues in one of the P1
loops. The significantly less favorable enthalpy for both pro-
tease variants is partially compensated for by large favorable
changes in the other component of the binding energy, en-
tropy, with (TS) increases of 4.5 and 13.4 kcal mol1
for T80V and T80N, respectively. One hypothesized reason for
enthalpy-entropy compensation in other systems was a differ-
ence in the amount of bound water molecules from one variant
to another that does not affect the overall binding affinity
drastically but does affect the entropy-enthalpy balance (4, 5,
13, 59). While this may account for 1- to 2-kcal mol1 changes
in enthalpy and entropy, the huge entropy-enthalpy compen-
sations observed in the case of T80V and T80N are probably
due to a combination of effects.
In the case of the Thr80 variants, changes in thermodynam-
ics are likely due to changes in the enzyme since the ligand,
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SQV, and the solvent were constant between the reactions. For
T80V, the mutation of polar threonine to hydrophobic valine
could explain the observed changes in enthalpy and entropy.
The loss of enthalpy in this case could be due to the inability of
valine to form internal hydrogen bonds within the protease
structure, while the increase in entropy could be due to the
release of ordered waters solvating hydrophobic valine upon
forming a complex with SQV. More ordered water would be
needed to solvate hydrophobic valine than is needed to solvate
the polar threonine; thus, more water would be released from
the active site of T80V when binding SQV. Additionally, a
valine would have more conformational freedom as it is not
restricted by a hydrogen bond to the backbone. Both aspara-
gine and threonine are polar residues, but asparagine is larger
and capable of forming polar interactions with residues in the
flap region. In the case of T80N, the 13.4-kcal mol1 more
favorable entropy could be due to the change in the flap dy-
namics that was observed in the MD simulation of the unli-
ganded form of the enzyme. In contrast to the other protease
variants, where the flaps are very flexible and a large loss of
conformational entropy within the protease occurs upon form-
ing a complex, the flaps of T80N are much less flexible. There-
fore, there is less conformational entropy to lose with T80N
and the binding would be entropically more favorable than
with the other variants. Thus, combining the results of these
biophysical measurements, the molecular role of Thr80 in the
HIV-1 protease is that of a small hydrophilic residue that
facilitates flap flexibility in the unliganded state while allowing
tight packing of the active site in the liganded state of the
enzyme. This mechanism may therefore account for the im-
portance and observed invariance of Thr80 within the HIV-1
protease.
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